Preferred Label : methysergide;
MeSH definition : An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes
the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but
has few of the properties of other ergot alkaloids. Methysergide is used prophylactically
in migraine and other vascular headaches and to antagonize serotonin in the carcinoid
syndrome.;
MeSH synonym : dimethylergometrin; methylmethylergonovine;
CISMeF synonym : alliance brand of methysergide maleate; novartis brand of methysergide maleate;
DeCS synonym : D sernil Sandoz; D sernil-Sandoz;
MeSH hyponym : Methysergide Maleate; methysergide dimaleate; UML-491; sansert; UML 491; UML491; Deseril; Désernil-Sandoz; Désernil Sandoz; Desril; Dimaleate, Methysergide; Maleate, Methysergide;
MeSH CAS label : Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-,
(8beta(S))-;
MeSH Related Number : methysergide maleate; 129-49-7 (Methysergide maleate); 361-37-5 (Methysergide); 2U7H1466GH;
Registry Number MeSH : 361-37-5;
Related CAS MeSH : 2U7H1466GH (Methysergide maleate);
Wikipedia link : https://en.wikipedia.org/wiki/Methysergide;
Codes EINECS : 206-644-0;
Is substance : O;
UNII : XZA9HY6Z98;
InChIKey : KPJZHOPZRAFDTN-ZRGWGRIASA-N;
Origin ID : D008784;
UMLS CUI : C0025842;
ATC code(s)
Allowable qualifiers
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes
the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but
has few of the properties of other ergot alkaloids. Methysergide is used prophylactically
in migraine and other vascular headaches and to antagonize serotonin in the carcinoid
syndrome.
http://www.lecrat.eu/?s=M%C3%A9thysergide
2013
France
French
pregnancy
methysergide
vasoconstrictor agents
methysergide
Methysergide Maleate
drug information
---
http://www.has-sante.fr/portail/jcms/c_1294640/dihydroergotamine-amdipharm-ikaran-lp-seglor-seglor-lyoc-tamik-dihydroergotamine-et-desernil-methysergide-derives-ergotes
http://www.has-sante.fr/portail/jcms/c_1294612/dhe-migraine-synthese-23052012
http://www.has-sante.fr/portail/jcms/c_1257411/dhe-amdipharm-23052012-avis-ct12061
http://www.has-sante.fr/portail/jcms/c_1257431/ikaran-23052012-avis-ct12075-11038
http://www.has-sante.fr/portail/jcms/c_1257339/seglor-23052012-avis-ct11066-12147
http://www.has-sante.fr/portail/jcms/c_1257452/tamik-23052012-avis-ct12044
http://www.has-sante.fr/portail/jcms/c_1257408/desernil-23052012-avis-ct12062-11053
2012
France
French
antimigraine preparations
migraine disorders
treatment outcome
insurance, health, reimbursement
administration, oral
methysergide
methysergide
Methysergide Maleate
injections
dihydroergotamine
Dihydroergotamine Mesylate
dihydroergotamine
Delayed-Action preparations
dihydroergotamine
Dihydroergotamine Mesylate
methysergide
Methysergide Maleate
guidelines for drug use
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-06/desernil_23052012_avis_ct12062_11053.pdf
http://www.has-sante.fr/portail/jcms/c_1256036/desernil
2012
France
French
evaluation of the transparency committee
antimigraine preparations
methysergide
methysergide
migraine disorders
cluster headache
vasoconstrictor agents
vasoconstrictor agents
serotonin antagonists
serotonin antagonists
adult
review literature as topic
product surveillance, postmarketing
risk assessment
retroperitoneal fibrosis
administration, oral
treatment outcome
insurance, health, reimbursement
Methysergide Maleate
Methysergide Maleate
methysergide
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-3058_desernil_sandoz_.pdf
http://www.has-sante.fr/portail/display.jsp?id=c_477425
2007
France
French
antimigraine preparations
evaluation of the transparency committee
Methysergide Maleate
tablets
methysergide
administration, oral
serotonin antagonists
vasoconstrictor agents
methysergide
insurance, health, reimbursement
migraine disorders
cluster headache
adult
treatment outcome
---